The Complete GLP-1 Medication Comparison Table (2026)
RES-000001
This table brings together every GLP-1-class medication covered in this knowledge base, active, discontinued, compounded, and investigational, in one place for direct comparison. Each medication links to a full, detailed guide covering dosing, side effects, and warnings.
| Medication | Active Ingredient | Manufacturer | Drug Class | Route | Frequency | Primary Indication(s) | Status |
|---|---|---|---|---|---|---|---|
| Semaglutide (generic) | Semaglutide | Novo Nordisk | GLP-1 | Injection / Oral | Weekly / Daily | Varies by brand | Active |
| Ozempic | Semaglutide | Novo Nordisk | GLP-1 | Injection / Tablet | Weekly / Daily | Type 2 diabetes, CV risk, kidney disease | Active |
| Wegovy | Semaglutide | Novo Nordisk | GLP-1 | Injection / Tablet | Weekly / Daily | Weight management, CV risk, MASH | Active |
| Rybelsus | Semaglutide | Novo Nordisk | GLP-1 | Oral tablet | Daily | Type 2 diabetes | Discontinued (May 2026, transitioned to Ozempic tablet) |
| Tirzepatide (generic) | Tirzepatide | Eli Lilly | GLP-1/GIP | Injection | Weekly | Varies by brand | Active |
| Mounjaro | Tirzepatide | Eli Lilly | GLP-1/GIP | Injection | Weekly | Type 2 diabetes, CV risk (HFpEF) | Active |
| Zepbound | Tirzepatide | Eli Lilly | GLP-1/GIP | Injection | Weekly | Weight management, obstructive sleep apnea | Active |
| Liraglutide (generic) | Liraglutide | Novo Nordisk | GLP-1 | Injection | Daily | Varies by brand | Active |
| Victoza | Liraglutide | Novo Nordisk | GLP-1 | Injection | Daily | Type 2 diabetes, CV risk | Active |
| Saxenda | Liraglutide | Novo Nordisk | GLP-1 | Injection | Daily | Weight management | Active |
| Dulaglutide (generic) | Dulaglutide | Eli Lilly | GLP-1 | Injection | Weekly | Varies by brand | Active |
| Trulicity | Dulaglutide | Eli Lilly | GLP-1 | Injection | Weekly | Type 2 diabetes, CV risk | Active |
| Exenatide (generic) | Exenatide | Amneal (generic) | GLP-1 | Injection | Daily / Weekly | Type 2 diabetes | Discontinued brands; generic available |
| Byetta | Exenatide | AstraZeneca | GLP-1 | Injection | Twice daily | Type 2 diabetes | Discontinued (October 2024) |
| Bydureon BCise | Exenatide (extended-release) | AstraZeneca | GLP-1 | Injection | Weekly | Type 2 diabetes | Discontinued (October 2024) |
| Adlyxin | Lixisenatide | Sanofi | GLP-1 | Injection | Daily | Type 2 diabetes | Active |
| Compounded Semaglutide | Semaglutide | Various compounding pharmacies | GLP-1 | Injection | Weekly | Not FDA-approved | Legally restricted (narrow 503A exceptions only, 2026) |
| Compounded Tirzepatide | Tirzepatide | Various compounding pharmacies | GLP-1/GIP | Injection | Weekly | Not FDA-approved | Legally restricted; status varies, verify with FDA directly |
| Retatrutide | Retatrutide | Eli Lilly | GLP-1/GIP/Glucagon | Injection | Weekly | Investigational (obesity, diabetes) | Not FDA-approved (NDA expected late 2026) |
| CagriSema | Cagrilintide + Semaglutide | Novo Nordisk | Amylin + GLP-1 | Injection | Weekly | Investigational (weight management) | Not FDA-approved (NDA filed December 2025) |
How to Read This Table
Drug Class distinguishes single-target GLP-1 medications from dual (GLP-1/GIP) and triple (GLP-1/GIP/Glucagon) agonists, which generally show stronger average effects due to their broader mechanism.
Status reflects availability as of 2026, several medications on this list are discontinued brands, legally restricted compounded versions, or investigational drugs not yet available by prescription. Always verify current status before assuming availability.
A Note on Compounded and Investigational Entries
Compounded semaglutide and tirzepatide are included for completeness, but their legal availability is narrow and actively changing, see their dedicated pages for current detail. Retatrutide and CagriSema are investigational and not available by prescription under any circumstances outside clinical trial enrollment.
References
- U.S. FDA prescribing information for each listed brand medication
- DailyMed prescribing information database
- Individual medication guides linked throughout this table, each with full source citations
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Explore the GLP-1 Tracker knowledge base for full guides on every medication listed above.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This table is for general informational purposes and is not medical advice. Medication availability and legal status change frequently, always verify current details with your provider, pharmacy, or the FDA directly.
glp-1-medication-comparison-table